CSIMarket
 


Atara Biotherapeutics Inc   (ATRA)
Other Ticker:  
 

Cumulative Atara Biotherapeutics Inc 's Quick Ratio for Trailing Twelve Months Period

ATRA's Quick Ratio for Trailing Twelve Months Period and Cash & cash equivalent, Current Liabilities growth


Select the Comparisons : Select the Ratio:

ATRA Quick Ratio for Trailing Twelve Months Period

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Current Liabilities Growth 9.47 % 13.49 % -33.17 % -25.4 % -16.14 %
Y / Y Cash & cash equivalent Growth -61.41 % -53.63 % -31.94 % -34.56 % -25.71 %
Quick Ratio for Trailing Twelve Months Period 2.34 2.95 3.67 3.58 3.68
Total Ranking # 877 # 816 # 763 # 898 # 930
Seq. Current Liabilities Growth 6.09 % 9.84 % -13.99 % 9.24 % 9.98 %
Seq. Cash & cash equivalent Growth -33.35 % -25.2 % -15.41 % -8.51 % -19.89 %


Quick Ratio for Trailing Twelve Months Period Comment for 12 Months ending at Sep 30 2023
On the trailing twelve months basis Due to rise in Current Liabilities in the III. Quarter to $79 millions, average cumulative Quick Ratio for Trailing Twelve Months Period decreased to 2.34 below Atara Biotherapeutics Inc average Quick Ratio for Trailing Twelve Months Period.
Quick Ratio for Trailing Twelve Months Period is the average cumulative value over the last four quarters.

Among companies operatig within Biotechnology & Pharmaceuticals industry 127 other companies have achieved higher Quick Ratio for Trailing Twelve Months Period than Atara Biotherapeutics Inc . While overall ranking remained unchanged compare to previous quarter at no. .

What is Quick Ratio?
Learn more about ATRA
Quick Ratio ATRA in the most recent quarter
Quick Ratio for Trailing Twelve Months Period Company Ranking
Within: No.
Industry # 128
Sector # 643
S&P 500 # 1200


Quick Ratio for Trailing Twelve Months Period Statistics
High Average Low
23.02 8.62 2.34
(Jun 30 2017)   (Sep 30 2023)




Companies with similar average Quick Ratio for Trailing Twelve Months Period for 12 months ending Sep 30 2023, within Biotechnology & Pharmaceuticals Industry Quick Ratio for Trailing Twelve Months Period
Surface Oncology Inc   6.41 
Bioatla Inc   6.39 
Prime Medicine Inc   6.31 
Cardiol Therapeutics inc   6.07 
Palisade Bio Inc   5.83 
Senti Biosciences Inc   5.74 
Polarityte Inc   5.66 
Zura Bio Limited  5.66 
Dyadic International Inc  5.59 
Ocugen Inc   5.55 
Denali Therapeutics Inc   5.48 
In8bio Inc   5.46 
Tarsus Pharmaceuticals Inc   5.40 
Fennec Pharmaceuticals Inc   5.32 
Miromatrix Medical inc   5.22 
X4 Pharmaceuticals Inc  5.15 
Twist Bioscience Corporation  5.11 
Finch Therapeutics Group Inc   5.10 
Opthea Limited  5.07 
Turnstone Biologics Corp   5.00 
Alector Inc   4.96 
Molecular Partners Ag  4.90 
Omega Therapeutics Inc   4.89 
Adverum Biotechnologies Inc   4.82 
Sutro Biopharma Inc   4.78 
Biontech Se  4.70 
Iovance Biotherapeutics Inc   4.67 
Spk Acquisition Corp   4.64 
Recursion Pharmaceuticals Inc   4.59 
Sophia Genetics Sa  4.56 




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com